Conference Coverage

TAVR cerebral protection device appears safe, effective

Publish date: June 7, 2016

 

AT EUROPCR 2016

References

Dr. Lansky replied that the much larger ongoing pivotal randomized, phase III REFLECT trial should provide definitive answers.

She reported receiving institutional research grant support from Keystone Heart, which produces the TriGuard device.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

VIDEO: Stenting in asymptomatic patients noninferior to endarterectomy at 5 years
MDedge Neurology
ISC: Carotid surgery, stenting offer patients balanced alternatives
MDedge Neurology
New postop pain guideline: Multiple approaches to target different pain mechanisms
MDedge Neurology
VIDEO: A better way to treat large intraventricular hemorrhages
MDedge Neurology
ISC: Thrombectomy shown highly cost-effective for stroke
MDedge Neurology
VIDEO: Ischemic-stroke thrombectomy use widens and refines
MDedge Neurology
High false positives found for Medtronic’s implantable AF detectors
MDedge Neurology
Guideline update shortens minimum DAPT duration in CAD
MDedge Neurology
Endovascular thrombectomy procedure volume for stroke may not affect outcomes
MDedge Neurology
Watchman registry provides reassuring answers on device safety
MDedge Neurology